A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
NCT07705334
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors who have progressed on or are intolerant to standard therapies. The study will consist of 2 parts: a dose escalation part (Phase 1a) and a dose expansion part (Phase 1b).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced or Metastatic Solid Tumors
- Triple Negative Breast Cancer (TNBC)
- HR+ Breast Cancer
- Colon Cancer
- Gastric Cancer
- Hepatecellular Carcinoma
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Mesothelioma
- Pancreatic Carcinoma Metastatic
- Hormone Refractory Prostate Cancer
- Soft Tissue Sarcomas
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- SHY Therapeutics
- Last updated on ClinicalTrials.gov
- September 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- HonorHealth Research Institute · Scottsdale, AZ
Texas · 2
- The University of Texas MD Anderson Cancer Center · Houston, TX
- NEXT Oncology · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.